Characteristics of recipients receiving first transplants for AML, ALL, CML, or MDS that are high-resolution typed for HLA-A, -B, -C, and -DRB1 and are 8/8 allele-matched or 7/8 allele-matched with single mismatch at Class I locus
| . | 8/8 Matched . | 7/8 with Study AAS . | 7/8 without Study AAS . | P . |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | ||
| Number of patients | 5282 | 1713 | 318 | |
| Number of centers | 166 | 155 | 93 | |
| Recipient age, median (range), y | 41 (<1-74) | 36 (<1-74) | 37 (<1-68) | <.0001 |
| Age at transplant, y | ||||
| 0-9 | 377 (7) | 166 (10) | 33 (10) | <.0001 |
| 10-19 | 523 (10) | 234 (14) | 40 (13) | |
| 20-29 | 744 (14) | 257 (15) | 50 (16) | |
| 30-39 | 870 (16) | 303 (18) | 48 (15) | |
| 40-49 | 1118 (21) | 352 (21) | 78 (25) | |
| 50 and older | 1650 (31) | 401 (23) | 69 (22) | |
| Male sex | 3001 (57) | 940 (55) | 170 (53) | .22 |
| Karnofsky prior to transplant >90 | 3425 (70) | 1141 (71) | 206 (69) | .79 |
| Disease at transplant | ||||
| AML | 2122 (40) | 677 (40) | 112 (35) | <.0001 |
| ALL | 1038 (20) | 395 (23) | 90 (28) | |
| CML | 1146 (22) | 380 (22) | 71 (22) | |
| MDS | 976 (18) | 261 (15) | 45 (14) | |
| Disease status at transplant | ||||
| Early | 3713 (70) | 1186 (69) | 219 (69) | .43 |
| Intermediate | 267 (5) | 104 (6) | 14 (4) | |
| Advanced | 1302 (25) | 423 (25) | 85 (27) | |
| Graft type | ||||
| Bone marrow | 2902 (55) | 1052 (61) | 199 (63) | <.0001 |
| PBSC | 2380 (45) | 661 (39) | 119 (37) | |
| Conditioning regimen | ||||
| Myeloablative | 4082 (77) | 1412 (82) | 268 (84) | <.0001 |
| Reduced intensity | 880 (17) | 229 (13) | 36 (11) | |
| Nonmyeloablative | 320 (6) | 72 (4) | 14 (4) | |
| In vivo T-cell depletion (ATG or Campath) | ||||
| Yes | 1266 (24) | 492 (29) | 75 (24) | .0003 |
| No | 4016 (76) | 1221 (71) | 243 (76) | |
| GVHD prophylaxis | ||||
| FK506 ± MTX ± other | 2617 (50) | 730 (43) | 133 (42) | <.0001 |
| CSA ± MTX ± other | 2303 (44) | 813 (47) | 162 (51) | |
| T-cell depletion | 159 (3) | 90 (5) | 16 (5) | |
| Other | 203 (4) | 80 (5) | 7 (2) | |
| Interval from diagnosis to TX – CML, mo | 13 (1-296) | 15 (2-309) | 12 (2-112) | .13 |
| Interval from diagnosis to TX – MDS, mo | 8 (<1-325) | 9 (<1-342) | 9 (<1-283) | .40 |
| HLA matching for HLA-A, -B, -C and -DRB1 | ||||
| 8/8 allele matched | 5282 (100) | 0 | 0 | <.0001 |
| Single MM at HLA-A | 0 | 631 (37) | 67 (21) | |
| Single MM at HLA-B | 0 | 226 (13) | 91 (29) | |
| Single MM at HLA-C | 0 | 856 (50) | 160 (50) | |
| Donor/recipient sex match | ||||
| Male/male | 2136 (40) | 573 (33) | 116 (36) | <.0001 |
| Male/female | 1349 (26) | 411 (24) | 80 (25) | |
| Female/male | 865 (16) | 367 (21) | 54 (17) | |
| Female/female | 932 (18) | 362 (21) | 68 (21) | |
| Donor/recipient CMV match | ||||
| Negative/negative | 1688 (32) | 526 (31) | 96 (30) | .0009 |
| Negative/positive | 1678 (32) | 485 (28) | 97 (31) | |
| Positive/negative | 696 (13) | 253 (15) | 49 (15) | |
| Positive/positive | 952 (18) | 382 (22) | 65 (20) | |
| Unknown donor or recipient CMV status | 268 (5) | 67 (4) | 11 (3) | |
| Donor age, median (range), y | 34 (18-61) | 36 (19-61) | 37 (19-58) | <.0001 |
| 18-29 | 1763 (33) | 436 (25) | 78 (25) | <.0001 |
| 30-39 | 1928 (37) | 660 (39) | 99 (31) | |
| 40-49 | 1279 (24) | 476 (28) | 100 (31) | |
| 50 and older | 312 (6) | 141 (8) | 41 (13) | |
| Year of transplant | ||||
| 1988 | 11 (<1) | 2 (<1) | 0 | <.0001 |
| 1989 | 37 (1) | 11 (1) | 2 (1) | |
| 1990 | 48 (1) | 16 (1) | 3 (1) | |
| 1991 | 73 (1) | 20 (1) | 7 (2) | |
| 1992 | 91 (2) | 37 (2) | 6 (2) | |
| 1993 | 94 (2) | 44 (3) | 10 (3) | |
| 1994 | 147 (3) | 54 (3) | 6 (2) | |
| 1995 | 143 (3) | 75 (4) | 17 (5) | |
| 1996 | 159 (3) | 64 (4) | 15 (5) | |
| 1997 | 193 (4) | 69 (4) | 14 (4) | |
| 1998 | 184 (3) | 74 (4) | 19 (6) | |
| 1999 | 210 (4) | 96 (6) | 23 (7) | |
| 2000 | 260 (5) | 99 (6) | 26 (8) | |
| 2001 | 255 (5) | 119 (7) | 26 (8) | |
| 2002 | 261 (5) | 74 (4) | 12 (4) | |
| 2003 | 321 (6) | 124 (7) | 19 (6) | |
| 2004 | 466 (9) | 148 (9) | 34 (11) | |
| 2005 | 562 (11) | 161 (9) | 24 (8) | |
| 2006 | 639 (12) | 153 (9) | 23 (7) | |
| 2007 | 630 (12) | 147 (9) | 18 (6) | |
| 2008 | 309 (6) | 93 (5) | 8 (3) | |
| 2009 | 189 (4) | 33 (2) | 6 (2) | |
| Median follow-up of recipients, mo (range) | 67 (3-264) | 74 (3-240) | 96 (3-234) | .0003* |
| . | 8/8 Matched . | 7/8 with Study AAS . | 7/8 without Study AAS . | P . |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | ||
| Number of patients | 5282 | 1713 | 318 | |
| Number of centers | 166 | 155 | 93 | |
| Recipient age, median (range), y | 41 (<1-74) | 36 (<1-74) | 37 (<1-68) | <.0001 |
| Age at transplant, y | ||||
| 0-9 | 377 (7) | 166 (10) | 33 (10) | <.0001 |
| 10-19 | 523 (10) | 234 (14) | 40 (13) | |
| 20-29 | 744 (14) | 257 (15) | 50 (16) | |
| 30-39 | 870 (16) | 303 (18) | 48 (15) | |
| 40-49 | 1118 (21) | 352 (21) | 78 (25) | |
| 50 and older | 1650 (31) | 401 (23) | 69 (22) | |
| Male sex | 3001 (57) | 940 (55) | 170 (53) | .22 |
| Karnofsky prior to transplant >90 | 3425 (70) | 1141 (71) | 206 (69) | .79 |
| Disease at transplant | ||||
| AML | 2122 (40) | 677 (40) | 112 (35) | <.0001 |
| ALL | 1038 (20) | 395 (23) | 90 (28) | |
| CML | 1146 (22) | 380 (22) | 71 (22) | |
| MDS | 976 (18) | 261 (15) | 45 (14) | |
| Disease status at transplant | ||||
| Early | 3713 (70) | 1186 (69) | 219 (69) | .43 |
| Intermediate | 267 (5) | 104 (6) | 14 (4) | |
| Advanced | 1302 (25) | 423 (25) | 85 (27) | |
| Graft type | ||||
| Bone marrow | 2902 (55) | 1052 (61) | 199 (63) | <.0001 |
| PBSC | 2380 (45) | 661 (39) | 119 (37) | |
| Conditioning regimen | ||||
| Myeloablative | 4082 (77) | 1412 (82) | 268 (84) | <.0001 |
| Reduced intensity | 880 (17) | 229 (13) | 36 (11) | |
| Nonmyeloablative | 320 (6) | 72 (4) | 14 (4) | |
| In vivo T-cell depletion (ATG or Campath) | ||||
| Yes | 1266 (24) | 492 (29) | 75 (24) | .0003 |
| No | 4016 (76) | 1221 (71) | 243 (76) | |
| GVHD prophylaxis | ||||
| FK506 ± MTX ± other | 2617 (50) | 730 (43) | 133 (42) | <.0001 |
| CSA ± MTX ± other | 2303 (44) | 813 (47) | 162 (51) | |
| T-cell depletion | 159 (3) | 90 (5) | 16 (5) | |
| Other | 203 (4) | 80 (5) | 7 (2) | |
| Interval from diagnosis to TX – CML, mo | 13 (1-296) | 15 (2-309) | 12 (2-112) | .13 |
| Interval from diagnosis to TX – MDS, mo | 8 (<1-325) | 9 (<1-342) | 9 (<1-283) | .40 |
| HLA matching for HLA-A, -B, -C and -DRB1 | ||||
| 8/8 allele matched | 5282 (100) | 0 | 0 | <.0001 |
| Single MM at HLA-A | 0 | 631 (37) | 67 (21) | |
| Single MM at HLA-B | 0 | 226 (13) | 91 (29) | |
| Single MM at HLA-C | 0 | 856 (50) | 160 (50) | |
| Donor/recipient sex match | ||||
| Male/male | 2136 (40) | 573 (33) | 116 (36) | <.0001 |
| Male/female | 1349 (26) | 411 (24) | 80 (25) | |
| Female/male | 865 (16) | 367 (21) | 54 (17) | |
| Female/female | 932 (18) | 362 (21) | 68 (21) | |
| Donor/recipient CMV match | ||||
| Negative/negative | 1688 (32) | 526 (31) | 96 (30) | .0009 |
| Negative/positive | 1678 (32) | 485 (28) | 97 (31) | |
| Positive/negative | 696 (13) | 253 (15) | 49 (15) | |
| Positive/positive | 952 (18) | 382 (22) | 65 (20) | |
| Unknown donor or recipient CMV status | 268 (5) | 67 (4) | 11 (3) | |
| Donor age, median (range), y | 34 (18-61) | 36 (19-61) | 37 (19-58) | <.0001 |
| 18-29 | 1763 (33) | 436 (25) | 78 (25) | <.0001 |
| 30-39 | 1928 (37) | 660 (39) | 99 (31) | |
| 40-49 | 1279 (24) | 476 (28) | 100 (31) | |
| 50 and older | 312 (6) | 141 (8) | 41 (13) | |
| Year of transplant | ||||
| 1988 | 11 (<1) | 2 (<1) | 0 | <.0001 |
| 1989 | 37 (1) | 11 (1) | 2 (1) | |
| 1990 | 48 (1) | 16 (1) | 3 (1) | |
| 1991 | 73 (1) | 20 (1) | 7 (2) | |
| 1992 | 91 (2) | 37 (2) | 6 (2) | |
| 1993 | 94 (2) | 44 (3) | 10 (3) | |
| 1994 | 147 (3) | 54 (3) | 6 (2) | |
| 1995 | 143 (3) | 75 (4) | 17 (5) | |
| 1996 | 159 (3) | 64 (4) | 15 (5) | |
| 1997 | 193 (4) | 69 (4) | 14 (4) | |
| 1998 | 184 (3) | 74 (4) | 19 (6) | |
| 1999 | 210 (4) | 96 (6) | 23 (7) | |
| 2000 | 260 (5) | 99 (6) | 26 (8) | |
| 2001 | 255 (5) | 119 (7) | 26 (8) | |
| 2002 | 261 (5) | 74 (4) | 12 (4) | |
| 2003 | 321 (6) | 124 (7) | 19 (6) | |
| 2004 | 466 (9) | 148 (9) | 34 (11) | |
| 2005 | 562 (11) | 161 (9) | 24 (8) | |
| 2006 | 639 (12) | 153 (9) | 23 (7) | |
| 2007 | 630 (12) | 147 (9) | 18 (6) | |
| 2008 | 309 (6) | 93 (5) | 8 (3) | |
| 2009 | 189 (4) | 33 (2) | 6 (2) | |
| Median follow-up of recipients, mo (range) | 67 (3-264) | 74 (3-240) | 96 (3-234) | .0003* |
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; CSA, cyclosporine; FK506, tacrolimus; MDS, myelodysplastic syndrome; MTX, methotrexate; PBSC, peripheral blood mobilized stem cell.
Log-rank P value.